Thistle Mary 4

What Happened Thistle Mary, a director of Q32 Bio, received an award/acquisition of 9,810 derivative shares on June 12, 2026. The reported grant shows a $0.00 price per share (derivative award), meaning these are awarded equity rights rather than an open-market purchase or sale. This is a grant of potential future shares (not an immediate cash transaction or sale).

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-16 (filed on the second business day after the transaction, which is timely).
• Amount: 9,810 shares granted; reported price: $0.00 (derivative award).
• Vesting/Exercise condition (Footnote F1): the underlying shares vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date.
• Shares owned after transaction: not specified in the provided filing details.
• No indication in the filing that shares were sold or otherwise transferred; this is a grant of future/derivative equity.

Context This filing records an equity award to a director (often used for compensation or retention). Because it’s a derivative award with vesting conditions and a $0.00 reported price, it does not represent an open-market purchase or sale and does not immediately change public float. For retail investors, grants signal compensation alignment with the company but do not necessarily reflect a director’s near-term market conviction.